Abstract
Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.
| Original language | English |
|---|---|
| Pages (from-to) | 177-189 |
| Number of pages | 13 |
| Journal | American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting |
| DOIs | |
| State | Published - 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Antineoplastic Agents/adverse effects
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Chemotherapy, Adjuvant
- History, 20th Century
- History, 21st Century
- Humans
- Immunotherapy
- Lung Neoplasms/drug therapy
- Medical Oncology/history
- Molecular Targeted Therapy
- Pneumonectomy
- Radiotherapy, Adjuvant
- Treatment Outcome
Fingerprint
Dive into the research topics of '50 Years of progress in the systemic therapy of non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver